The Milan criteria: No room on the metro for the king?

Liver Transplantation

Volumn 16, Issue 3, 2010, Pages 252-255

  Marsh, J Wallis ^a   Schmidt, Carl ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; MINICHROMOSOME MAINTENANCE PROTEIN 2;

ADJUVANT THERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; DISEASE COURSE; EDITORIAL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR RECURRENCE; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; HEALTH PLANNING GUIDELINES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; RESOURCE ALLOCATION; RISK FACTORS; TISSUE AND ORGAN PROCUREMENT; TUMOR BURDEN;

EID: 77749334515     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22037     Document Type: Editorial

References (34)

1. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma - epidemiological trends and risk factors. Dig Dis 2009;27:80-92.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
3. Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 2005;25:171-180.
4. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000;88:538-543.
5. Yao FY, Kerlan RK Jr, Hirose R, Davern TJ III, Bass NM, Feng S, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48: 819-827.
6. Hanje AJ, Yao FY. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant 2008;13:234-240.
7. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181-200.
8. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
9. Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008; 8:1982-1989.
10. Marsh JW, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl 2003;9: 693-696.
11. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009;49:832-838.
12. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NR, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-2596.
13. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246:502-509.
14. Marshall AE, Rushbrook SM, Vowler SL, Palmer CR, Davies RJ, Gibbs P, et al. Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. Liver Transpl 2010;16: 279-288.
15. Barakat O, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J, Skolkin M, et al. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis. Liver Transpl 2010;16:289-299.
16. Marsh JW, Finkelstein SD, Demetris AJ, Swalsky PA, Sasatomi E, Bandos A, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl 2003;9:664-671.
17. Finkelstein SD, Marsh W, Demetris AJ, Swalsky PA, Sasatomi E, Bonham A, et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology 2003; 37:871-879.
18. Dvorchik I, Schwartz M, Fiel MI, Finkelstein SD, Marsh JW. Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl 2008;14:443-450.
19. Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol 2008;49:581-588.
20. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Kaiser GM, Schmid KW, Baba HA. Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. J Clin Pathol 2009;62:690-693.
21. Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, Chen G, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 2006;5:808-814.
22. Fiorentino M, Altimari A, Ravaioli M, Gruppioni E, Gabusi E, Corti B, et al. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin Cancer Res 2004;10:1789-1795.
23. Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006;44:1012-1024.
24. Michalopoulos GK. Flexible lineage specifications of adult hepatic cells, associated molecular pathways, and their relationship to liver cancer. Cell Transplant 2006; 15(suppl 1):S67-S68.
25. Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, Kim YJ, Thorgeirsson SS. Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 2009;69:4059-4066.
26. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28:3526-3536.
27. De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe EB, et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 2009;9:1158-1168.
28. Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, et al. Outcomes of neo-adjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248:617-625.
29. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94:572-586.
30. Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12: 1260-1267.
31. Bruix J, Fuster J, Llovet J. Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. Liver Transpl 2003;9:700-702.
32. Volk ML, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 2008;8:839-846.
33. Marsh JW, Dvorchik I. Should we biopsy each liver mass suspicious for hepatocellular carcinoma before liver transplantation? - yes. J Hepatol 2005;43:558-562.
34. Cady B. Basic principles in surgical oncology. Arch Surg 1997;132:338-346.